Tetragenics Inc., of Arlington, Mass., said it is collaborating with Modiquest Research BV, of Oss, the Netherlands, for the discovery and optimization of monoclonal antibodies (MAbs), including those directed against difficult target antigens with low immunogenicity. The alliance is focused on the discovery of MAbs against KCa3.1, a well-validated target for fibrosis, vasculoproliferative disorders and immunomodulation to treat autoimmune and inflammatory disorders. Financial terms of the deal were not disclosed.